Objective: To evaluate the satisfaction, effectiveness, and usability of a telerehabilitation programme for Parkinson’s disease (PD) patients. Design: Prospective cohort study. Subjects/Patients: PD patients based on the diagnostic criteria for clinically established or probable PD published by the International Parkinson and Movement Disorder Society. Methods: The telerehabilitation was conducted twice a week via a Zoom meeting platform, using pre-recorded rehabilitation contents shared during the sessions. In this study we administered several questionnaires, i.e., a self-report questionnaire on the effectiveness of telerehabilitation, the Parkinson’s Disease Questionnaire-39 (PDQ-39), and the Telehealth Usability Questionnaire (TUQ), in order to evaluate the satisfaction, effectiveness, and usability of our telerehabilitation programme. Results: Fifty-six PD patients were included in the analysis. After 6 months, 91.1% expressed satisfaction with the telerehabilitation and 91.9% reported telerehabilitation had helped them develop an exercise routine, but the PDQ-39 showed no significant improvement in quality of life. The TUQ showed higher scores for Usefulness (76.1%), Ease of Use and Learnability (73.5%), Interface Quality (75.4%), and Satisfaction and Future Use (82.2%). Conclusion: Satisfaction with telerehabilitation was high, particularly with regard to positive effects on emotional well-being. Telerehabilitation usability was also found to be high.
Potential Psychosis Induced by Sustained High Plasma Levodopa Concentration via Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson’s Disease: A Case Report
Levodopa Pharmacokinetics in Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient with Parkinson
A previous postmortem study of men with Christianson syndrome, a disorder caused by loss-of-function mutations in the gene SLC9A6, reported a mechanistic link between pathologic tau accumulation and progressive symptoms such as cerebellar atrophy and cognitive decline. This study aimed to characterize the relationships between neuropathologic manifestations and tau accumulation in heterozygous women with SLC9A6 mutation. We conducted a multimodal neuroimaging and plasma biomarker study on 3 middle-aged heterozygous women with SLC9A6 mutations (proband 1: mid-50s; proband 2: early 50s; proband 3: mid-40s) presenting with progressive extrapyramidal symptoms. Examinations included 11C-PiB PET; 18F-florzolotau PET; structural MRI; and plasma measures of neurofilament light chain (NfL) polypeptide, glial fibrillary acidic protein, phosphorylated (p)Tau181, Aβ40, and Aβ42. Neuroimaging results of all 3 patients were compared with those of 12 healthy age-matched women (49.8 ± 4.7 years) while plasma biomarker levels of probands 1 and 2 were compared with those of 14 age-matched healthy women (54.1 ± 9.0 years). Proband 1 was diagnosed with Parkinson disease while probands 2 and 3 were diagnosed with atypical parkinsonism. 11C-PiB PET results were negative in all patients. 18F-florzolotau PET revealed focal tau accumulations in all 3 patients, predominantly in the striatum contralateral to motor symptoms. Moreover, greater extrapyramidal symptom severity was associated with higher standardized uptake value ratios (SUVRs) for 18F-florzolotau in the striatum. Multiple comparisons showed significantly higher 18F-florzolotau SUVR values in both the caudate and putamen of proband 1, who exhibited the most severe extrapyramidal signs, while no significant increases in 18F-florzolotau SUVR values were detected in any brain region of probands 2 and 3. Structural MRI revealed slightly lower regional subcortical and gray matter volumes in all patients but not significant after multiple comparisons. Finally, plasma NfL concentration was significantly higher in probands 1 and 2 compared with healthy controls. Our 18F-florzolotau PET analysis revealed greater tau accumulation in the striatum of heterozygous women with SLC9A6 mutation associated with worsening extrapyramidal symptom severity. The heterozygosity of loss-of-function SLC9A6 mutations further suggests that tauopathy may be a primary contributor to extrapyramidal signs.
7 May 2025 in Tremor and Other Hyperkinetic Movements
Background: Essential tremor (ET) is primarily characterized by action tremor, but is also associated with various non-motor symptoms (NMS). However, the diagnostic relevance of NMS in ET remains unclear. This study aimed to compare NMS and motor symptoms of ET with those of Parkinson’s disease-tremor dominant type (PD-TDT) and healthy controls (HCs) and to identify the presence and diagnostic relevance of NMS. Methods: Twenty-three ET patients, 23 PD-TDT patients, and 22 HCs were enrolled. Diagnoses of ET and PD were confirmed using Movement Disorder Society (MDS) criteria and Dopamine transporter single-photon emission computed tomography. Motor symptoms, NMS and quality of life (QOL) were evaluated using validated scales, including the Clinical Rating Scale for Tremor (CRST), MDS-Unified Parkinson’s Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale for Parkinson’s Disease (NMSS), Odor Stick Identification Test for Japanese (OSIT-J), and Quality of Life in Essential Tremor Questionnaire (QUEST). Results: ET patients had significantly higher NMSS total scores and MDS-UPDRS part IB scores than HCs, with more severe sleep disturbances, fatigue, and urinary problems. CRST scores were significantly correlated with QUEST scores. Logistic regression identified CRST Part B and OSIT-J as key factors distinguishing ET from PD-TDT, with 87% sensitivity and 90% specificity. Discussion: ET patients showed more severe NMS than HCs. Differentiating ET from PD-TDT requires motor and sensory assessments, highlighting the diagnostic relevance of NMS. Comprehensive evaluation is essential for accurate diagnosis and management of ET.
3 August 2026 in Movement Disorders Clinical Practice